Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2939-2942

  Chadwick, D ^a   Ankcorn, M ^a   Sarfo, F ^b   Phillips, R ^b,c   Fox, Z ^d   Garcia, A ^d,e   Appiah, L ^b   Bedu Addo, G ^b,c   Geretti, A M ^d,e  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Africa; Antiviral; HBV

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GENE MUTATION; GHANA; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; COINFECTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GHANA; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TRANSAMINASES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84869429990     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks333     Document Type: Article

References (10)

1. Burnett RJ, François G, Kew MC. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 2005; 25: 201-13.
2. Geretti AM, Patel M, Sarfo FS et al. Detection of highly prevalent hepatitis B virus co-infection among HIV-seropositive persons in Ghana. J Clin Microbiol 2010; 48: 3223-30.
3. Sheng WH, Chen MY, Hsieh SM et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38: 1471-7.
4. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6.
5. Hoffmann CJ, Charalambous S, Martin DJ et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47: 1479-85.
6. Idoko J, Meloni S, Muazu M et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49: 1268-73.
7. Law WP, Dore GJ, Duncombe CJ et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17: 2191-9.
8. Cooley L, Ayres A, Bartholomeusz A et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17: 1649-57.
9. Collini P, Schwab U, Sarfo S et al. Sustained immunological responses to HAART at 36 months in a Ghanaian HIV cohort. Clin Infect Dis 2009; 48: 988-91.
10. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.